A. Eder

发表

Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway

G. Mills, R. Bast, M. Mao, 1999, Oncogene.

Lysophosphatidic acid is a bioactive mediator in ovarian cancer.

Gordon B Mills, Janos L Tanyi, G. Mills, 2002, Biochimica et biophysica acta.

Specific keynote: molecular therapeutics in ovarian cancer.

G. Mills, E. Kohn, W. Kuo, 2003, Gynecologic oncology.

Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.

G. Mills, F. Claret, J. Wiener, 2007, International journal of oncology.

Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2.

G. Mills, T. Sasagawa, M. Mao, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment

S. Fuller, A. Eder, A. Huovila, 1992, The Journal of cell biology.

Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias.

P. Krammer, A. Eder, K. Debatin, 1995, Blood.

Lysophospholipid Growth Factors in the Initiation, Progression, Metastases, and Management of Ovarian Cancer

G. Mills, M. Mao, R. Lapushin, 2000, Annals of the New York Academy of Sciences.

Phosphoinositide 3-Kinase Regulation of T Cell Receptor-mediated Interleukin-2 Gene Expression in Normal T Cells*

T. Franke, J. Ashwell, A. Eder, 1998, The Journal of Biological Chemistry.

Identification of a Phosphothionate Analogue of Lysophosphatidic Acid (LPA) as a Selective Agonist of the LPA3 Receptor*

G. Mills, X. Fang, J. R. Erickson, 2003, The Journal of Biological Chemistry.

Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells.

G. Mills, J. Gu, J. Roth, 2002, Gynecologic oncology.

Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.

G. Mills, D. Fishman, M. Stack, 2002, Cancer treatment and research.

Lysophosphatidic acid and ovarian cancer: a paradigm for tumorogenesis and patient management.

G. Mills, M. Mao, T. Furui, 2001, Prostaglandins & other lipid mediators.

Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis

J. Ashwell, A. Eder, L. King, 1997, Molecular and cellular biology.

Bacterial death induced by expression of the intracellular portion of human Fas

Yili Yang, J. Ashwell, A. Eder, 1999, Cell Death and Differentiation.

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.

Yiling Lu, Gordon B Mills, Hongwei Wang, 2003, Seminars in oncology.

Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.

Gordon B Mills, Isabelle Bedrosian, Joe W Gray, 2005, Proceedings of the National Academy of Sciences of the United States of America.

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.

G. Mills, K. Siminovitch, Yiling Lu, 2001, Seminars in oncology.

T cell-specific negative regulation of transcription of the human cytokine IL-4.

P. Krammer, M. Li‐Weber, A. Eder, 1992, Journal of immunology.

Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.

G. Mills, R. Bast, M. Mao, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The 5' region of the human interleukin 4 gene: structure and potential regulatory elements.

P. Krammer, A. Eder, H. Krafft-Czepa, 1988, Nucleic acids research.

Molecular therapeutics in ovarian cancer

G. Mills, E. Kohn, W. Kuo, 2003 .